Date: 2015-10-05
Type of information: R&D agreement
Compound: oligomers
Company: Crossbeta Biosciences (The Netherlands) Servier (France)
Therapeutic area: Neurological diseases - CNS diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On October 5, 2015, Crossbeta Biosciences and Servier announced their collaboration in severalresearch projects involving the use of Crossbeta’s technology for generating stable oligomers. Crossbeta and Servier will jointly develop multiple oligomer types that will be used by Servier for its preclinical research programs in CNS. Misfolded proteins and oligomers are known to play an important role in various pathologies, including Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis and Huntington’s disease.
Financial terms:
Latest news:
